License Termination Notice and the Beginning of Conflict

Ligand Pharmaceuticals (LGND) has abruptly notified Viking Therapeutics (VIKN) of its intention to terminate the license agreement for the thyroid hormone receptor beta (TRβ) agonist program, originally signed in 2014. Ligand alleges that Viking failed to fulfill its contractual obligations by not exerting 'Commercially Reasonable Efforts' in the development and commercialization of VK2809, a candidate drug for metabolic dysfunction-associated steatohepatitis (MASH), and VK0214, a treatment for X-linked adrenoleukodystrophy (X-ALD). Viking immediately issued an official statement refuting the claims, asserting that it has fully complied with its contractual obligations and foreshadowing legal disputes. The conflicting positions of the two companies raise significant uncertainties regarding the future of their key pipeline assets, particularly as they approach Phase 3 trials.

Dominance in Obesity Treatment and Clash of Priorities

The root cause of this conflict appears to stem from the remarkable clinical success of Viking's obesity treatment candidate, VK2735 (a dual GLP-1/GIP agonist). Viking is currently conducting a Phase 3 trial of the subcutaneous formulation and has recently obtained positive Phase 2 data for the oral formulation, leading the company to focus its development efforts primarily on its obesity pipeline. As a result, the TRβ program, which was originally licensed from Ligand, has received relatively less attention in company presentations and communications. This has led Ligand, which was expecting royalty and milestone payments, to strongly object. This situation represents a typical case where a biotech company, with limited resources, concentrates on a specific star pipeline asset, leading to a misalignment of strategic goals with its existing partner.

Value of Each Company's Pipeline and Market Prospects

The subject of the dispute, VK2809, has demonstrated promising results in the Phase 2b VOYAGE study, achieving a 75% MASH resolution rate at 52 weeks, indicating its potential to be a best-in-class asset. With the global MASH treatment market projected to grow to over $20 billion by 2030, VK2809 is considered a strong competitor to resmetirom (Rezdiffra), the first drug approved by Madrigal Pharmaceuticals (MDGL). Furthermore, VK0214, a treatment for a rare disease, has also shown significant reductions in very long-chain fatty acids (VLCFAs) in a Phase 1b trial, targeting the market currently occupied by Bluebird Bio's gene therapy, Skysona. The potential loss of control over these programs, which have significant market potential, could have a significant impact on the value of both companies.

Contract Termination Scenarios and Investment Guidelines

If Ligand's contract termination is finalized and the rights to the TRβ program revert to Ligand, Viking will be required to transfer all intellectual property (IP) related to the asset to Ligand through a reverse license agreement. Ligand plans to either sell the rights to a third party for a low single-digit royalty or independently develop the program after regaining control. On the other hand, Viking will be able to focus on the independent commercialization of its obesity treatment, VK2735, but will also suffer the loss of a key pipeline asset and the elimination of milestone payments. Investors should carefully consider the partnership contract structure and the impact of the 'commercially reasonable efforts' clause on corporate value, beyond simply evaluating the success of clinical data.